News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Advanced Clear Cell Renal Cell Carcinoma: Putting Advances Into Practice

EP. 1: Evaluation of Risk for Frontline Advanced/Metastatic Clear Cell RCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

EP. 2: Clinical Trials Defining the NCCN Guidelines for Frontline Treatment of mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

EP. 3: Applying Clinical Trial Data for Treatment of mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

EP. 4: Patient Factor Consideration for Treatment of mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

EP. 5: Evaluating Long-Term Follow-Up Data for Treatment of mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

EP. 6: CheckMate 9ER: Phase 3 Trial of Frontline Nivolumab + Cabozantinib

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

EP. 7: Choosing Upfront Therapy for mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

EP. 8: Evaluating Safety Profiles of Upfront Regimens for mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

EP. 9: Treating Side Effects of Therapy for mRCC with Steroids

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

EP. 10: Tailored Therapy Approaches for Upfront mRCC Treatment

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

EP. 11: Choosing Second-Line Therapy in Treatment of mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

EP. 12: Clinical Trials Shaping Treatment in Relapsed/Refractory mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

EP. 13: Strategies for Switching From Frontline Therapy to Second-Line Therapy in mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

EP. 14: Treating Patients With mRCC Beyond Second-Line

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

EP. 15: Future of Treating mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Trending on OncLive

HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA

TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC

Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis

SERENA-6 Meets PFS2 End Point With Early Switch to Camizestrant in ER+/HER2-Negative, ESR1-Mutated Advanced Breast Cancer

Dr Eads on Early Data for CDH17-Directed CAR T-Cell Therapy in R/R GI Cancers